Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange Detected- Added a government funding notice and operating status guidance, and added version 3.2.0. - Removed version 3.1.0.SummaryDifference4%
- Check15 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, indicating a new release. The 'Back to Top' navigation element was removed, a minor UI change.SummaryDifference0.2%
- Check36 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while several key medical topics and terms related to lung cancer and pembrolizumab have been removed.SummaryDifference3%
- Check58 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.